1 中 婴幼儿人群中 CVA16 中和抗体与 CVA16 手足口病的相关性研究 毛群颖 1 ∆ ,高帆 1 ∆ ,卞莲莲 1 ,胡亚林 2 ,姚昕 1 ,鲁卫卫 3 ,李秀玲 3 ,梁争论 1 1.中国食品药品检定研究院 卫生部生物技术产品检定方法及标准化重点实验室,北京 100050; 2.华兰生物工程股份有限公司,河南 新乡 453007; 3.国药中生生物技术研究院有限公司,北京 101111 摘要:目的 分析婴幼儿中柯萨奇病毒 A 组 16 型(coxsackievirus A16, CVA16)中和抗体对 CVA16 手足口病(hand-foot-mouth disease, HFMD)的预防作用。 方法 随访 2012 年 1 月—2014 年 1 月期间江苏省 180 名婴幼儿人群(6~<36 月龄),主动监测 CVA16-HFMD,分别采集 0 d、2 个月、8 个月和 24 个月的系列血样,并检测其 CVA16中和抗体。 结果 该人群在随访 93.9~141 d 期间发生了 1 起 CVA16 流行,共报告 10 例 CVA16 引起的 HFMD。中和抗体结果显示,在 CVA16 流行前(2 个月)CVA16 中和抗体阴性的 153 例中,共有 10 例确诊为 CVA16-HFMD(6.5%),49 例在流行后(8 个月)出现中和抗体阳转(阳转率为 32.0%)。而在流行前 CVA16 中和抗体阳性的 27例中,无 1 例患 CVA16- HFMD,8 例流行后呈中和抗体 4 倍及以上升高,占 31.7%。10 例 CVA16-HFMD 患者在流行后中和抗体均出现明显升高,较流行前平均升高 51.71 倍。 结论 婴幼儿人群中的 CVA16 中和抗体,可预防CVA16 感染导致的 HFMD。 关键词:手足口病;柯萨奇病毒 A 组 16 型;中和抗体;相关性 中图分类号: R512.5 文献标志码: A 文章编号: DOI: The correlation between CVA16 neutralizing antibody and CVA16 diseases in infants and children MAO Qun-ying * , GAO Fan, BIAN Lian-lian, HU Ya-lin, YAO Xin, LU Wei-wei, LI Xiu-ling, LIANG Zheng-lun *National Institutes for Food and Drug Control, Key Laboratory of verification methods and standardization of biotechnology products, Ministry of Health, Beijing 100050 Corresponding author: Liang Zheng-lun, E-mail: Lzhenglun@126.com Abstract: Objective To investigate the protective effect of coxsackievirus A16 (CVA16) neutralizing antibodies (NAbs) against CVA16-associated hand, foot and mouth disease (HFMD) in infants and children. Methods A total of 180 participants aged 6— <36 months age were followed from January, 2012 to January, 2014. CVA16-HFMD associated medical events were recorded through a surveillance system and diagnosed by RT-PCR. From this cohort, serial sera from 180 participants were collected and detected CVA16 NAbs at 0 d, 2, 8 and 24 months. Results There was a CVA16 epidemic in this population during 93.9—141d of the follow-up. There were 10 cases recorded and diagnosed as CVA16-associated HFMD at this epidemic. Among 153 participants with CVA16 NAbs negative before CVA16 epidemic (2m), 10 cases were diagnosed as CVA16-HFMD, and 49 participants were observed seraconversion (seroconversion rate 32.0%) after the CVA16 epidemic (8 months). However, there was no CVA16-HFMD case found from 27 participants who were CVA16 NAbs-positive before the epidemic, among of them, the CVA16 NAbs titers of 8 participants increased at least four-folds (seroconversion rate 31.7%) against pre-epidemic. The CVA16 NAbs for 10 CVA16-HFMD cases all increased significantly compared with pre-epidemic, the geometric mean fold-increase of CVA16 NAbs was 51.71. Conclusion The CVA16 NAbs could protect HFMD caused by CVA16 infection in infants and children. Key words: Hand, foot and mouth disease (HFMD); Coxsackie virus A16(CVA16); Neutralizing antibody(Nab); Correlation 柯萨奇病毒A组16型(coxsackievirus A16, CVA16)